Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post menopausal women whose disease has progressed despite tamoxifen therapy anastrozole ARIMIDEX, Zeneca, letrozole FEMARA, Novartis and vorozole RIVIZOR, Janssen <a href="https://buylasixon.com/" / rel="nofollow ugc">lasix kidney function</a>